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centage of patients aged 65–74 years with comorbidities was
52.9% higher than people aged 25–34 years old (p < 0.05). For
all cohorts, regardless of age, one of four patients with T2D coin-
cides with hypertension, one of ten patients with T2D coincides
with hyperlipidemia, and one of three patients with T2D coin-
cides with both hypertension and hyperlipidemia. In 2003, the
frequency of physicians’ visits for T2D patients with hyperten-
sion and hyperlipidemia was 2.3 times higher than for T2D
patients without comorbidities (p < 0.01). In terms of T2D
comorbidities, a major trigger for physicians to prescribe a drug
is the coexistence of both hypertension and hyperlipidemia.
CONCLUSIONS: The analysis of T2D incidence trends demon-
strates that developing disease management strategies for physi-
cians should include in their judgment, the fact that in a majority
of cases, patients have T2D coinciding with cardiovascular dis-
eases and hyperlipidemia.
PDB7
CLINICAL JUDGMENT OF DRUG THERAPY FOR TYPE-2
DIABETES PATIENTS AND RESULTS OF HBA1C TESTS
Lipskiy N
Surveillance Data Inc, Plymouth Meeting, PA, USA
OBJECTIVE: The goal of this study is to evaluate physicians’
prescribing behavior based on the results of Hb1Ac tests for
patients with type-2 diabetes. METHODS: The study design was
retrospective covering the 12-month longitudinal period June,
2003 through May, 2004. We used a three-month look back
period and a three-month look forward period for the validation
of pre and post test (HbA1c) therapy. The study was based on
the analysis of electronic CMS1500 claims for 33,764 unique
patients (HIPAA compliant) and their results from the most
recent HbA1c tests. Patients’ medication was assessed through
NCPDP electronic claims utilizing NDC codes and drug classes.
Analysis included calculations of descriptive statistics and regres-
sion modeling. RESULTS: The high level of HbA1c was discov-
ered during laboratory testing where a higher percentage of
patients without medication were placed on medication. In par-
ticular, within a category of patients with HbA1c greater than
or equal to 9mg/dL, this switch occurred 32.1% more frequently
then within a category of patients with HbA1c less than 7mg/dL
(p < 0.01). For patients with HbA1c greater than or equal to 9
mg/dL, the likelihood to change an existing therapy was 64.2%
higher than for patients with HbA1c less than 7mg/dL (p < 0.01).
Also, for people with a high level of Hb1Ac, the likelihood to
switch from monotherapy to polytherapy was 1.6 times higher
than for people with a low level of testing. CONCLUSIONS: 
For patients with type-2 diabetes, a level of Hb1Ac is one of 
the important predictors of change in a physician’s prescribing
behavior. High levels of HbA1c most likely will cause a switch
from just a dietary and exercise regimens to additional medica-
tion component.
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PREVALENCE OF DIABETES MELLITUS AND TREATMENT
PATTERNS BASED ON CLASSIFICATION OF BODY MASS
INDEX AMONG ADULTS
Suh DC, Shin HC,Vo L,Valiyeva E, Barone JA
Rutgers University, Piscataway, NJ, USA
OBJECTIVES: To examine trends of diabetes mellitus (DM)
prevalence in adults and to investigate treatment patterns and
HbA1c control according to their body mass index (BMI) clas-
siﬁcation. METHODS: This study used the Third National
Health and Nutrition Examination Survey (NHANES III for
1988–1994) and NHANES 2001–2002, representing a national
sample of the non-institutionalized civilian US population. Study
patients were identiﬁed if they were ≥20 years old, were previ-
ously diagnosed with DM by a physician or is currently using
DM therapy (insulin or a hypoglycemic agent). DM patients
were classiﬁed as normal (BMI < 25), overweight (BMI: 25–29),
or obese (BMI ≥ 30). Data were analyzed using SAS and
SUDAAN statistical software. RESULTS: The age-adjusted
prevalence of DM signiﬁcantly increased from 5.4% in
1988–1994 to 7.1% in 2001–2002 (increase of 1.7%: p < 0.05).
In 2001–2002, DM was more prevalent in overweight patients
(6.1%) and obese patients (10.5%) than in normal weight
patients (4%). These trends were similar in 1988–1994. More
DM patients (80% of overweight and 87% of obese patients)
received treatment in 2001–2002 than during 1988–1994 (70%
and 78%) (increases: p = 0.05 respectively). Patients were treated
with oral antihyperglycemics only most frequently (56%), fol-
lowed by insulin only (17%), and with both insulin and an oral
agent (9%). Overall, mean HbA1c decreased from 7.7% (57%
of DM-patients: HbA1c ≥ 7%) in 1988–1994 to 7.5% (50% of
DM-patients: HbA1c ≥ 7%) in 2001–2002 (p = 0.24). CON-
CLUSIONS: Over the past decade, DM has become more preva-
lent in US adults, more overweight and obese DM patients have
received treatment, yet 20% of overall DM patients still have not
received treatment. In 2001–2002, half of diabetic patients did
not control their HbA1c level and diabetic patients who were
obese were less likely to control their HbA1c compared to
patients who were normal weight.
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HEMOGLOBIN A1C (A1C) IN A DIABETIC LATINO
POPULATION
Aranda GA, Bonnet PO, Johnson KA
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To investigate the association between a lower
A1c (a measure of better diabetes control) and multiple health
system and individual variables in a Latino population.
METHODS: Data were obtained from the Los Angeles Latino
Eye Study (LALES) and included 6980 participants who were
>40 years old. Subjects with a physician diagnosis and those
without were stratiﬁed and compared. Continuous variables
were summarized using means, standard deviations and T-tests.
Categorical variables were summarized using frequency tables
and Chi-square tests. Multivariate linear regression was per-
formed on subjects with diabetes. P-value less than 0.05 were
considered statistically signiﬁcant. RESULTS: There were 1095
subjects with DM resulting in a prevalence of 18%, 73.0% of
subjects were married or living with their partner, 43.4% of 
subjects were males, 65.9% of subjects had insurance coverage,
and 3.8% of the subjects without a diagnosis had A1c values
that were above the diabetic goal, indicating probable diabetes
disease. Diabetics were older than non-diabetics (57.8 vs. 53.9;
p < 0.0001), insured (73.9% vs. 64.2%; p < 0.0001) and had a
higher percentage of individuals with a household income less
than $20,000 (55.8% vs. 49.6%; p = 0.0002). In total, 57.4%
of diabetics were using oral anti-diabetic medication alone, 5.9%
were using insulin alone, 3.6% were using diet alone and 15.3%
were using a combination of oral medication and insulin. Mul-
tivariate linear regression analysis (R2 = 0.1225, p < 0.0001)
showed that being older, single, insured, male and a lower
income was associated with a lower A1c. Also fewer disease
years, higher BMI, on diet vs. combination treatment were asso-
ciated with a lower A1c. How much the subjects have adopted
the American culture, expressed as an acculturation score, was
not signiﬁcantly associated with A1c. CONCLUSIONS: Though
this study did not measure severity of disease and medication
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adherence, some factors associated with better diabetes control
were identiﬁed.
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ECONOMIC BURDEN OF DIABETIC RETINOPATHY IN
FLORIDA: A PILOT STUDY EXPLORING THE AMOUNT SPENT
USING PRINCIPLE DIAGNOSES
Batiste L, Xiao H
Florida A & M University,Tallahassee, FL, USA
OBJECTIVE: The objective of this study is to determine the
direct medical costs associated with patients who have diabetic
retinopathy and their co-morbidities in the state of Florida.
METHODS: The study was a non-randomized, secondary data
analysis using the Florida Ambulatory Patient Data from 2001.
It was a cross-sectional analysis using the individual patient as
the unit of analysis. The ICD-9 Code 362.02 was used to extract
patients with a principle diagnosis of proliferative diabetic
retinopathy (PDR). The ICD-9 Codes 362.01 and 362.10 were
used to extract patients with a principle diagnosis of nonprolif-
erative diabetic retinopathy (NDR). ICD-9 Code 362.83 was
used to extract patients with macular edema (ME). Patient char-
acteristics along with total charges were extracted for each of
these patients. RESULTS: The total charges for Asian, African
American, and White Hispanic are signiﬁcantly lower than the
total charges for Caucasians. However, Black Hispanics have a
statistically signiﬁcant higher total charge than Caucasians.
Patients with Medicare, Medicare HMO, Medicaid, commercial
HMO, and commercial PPO, have statistically signiﬁcant higher
total charges than patients with commercial insurance. Both
PDR and BDR are associated with statistically signiﬁcant greater
total charges than patients with NDR. Yet, the total charges for
ME are signiﬁcantly lower than those for NDR. This model 
is statistically signiﬁcant. CONCLUSIONS: Total charges are
affected by patient characteristics and severity of diabetic
retinopathy. In the state of Florida for 2001, $3,885,952 were
spent on treating patients with diabetic retinopathy and their 
co-morbidities in the ambulatory setting.
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EVALUATION OF THE CLINICAL OUTCOME AND FINANCIAL
COSTS OF DELAYING THE ONSET OF FRANK 
TYPE-2 DIABETES
McEwan P1, Peters JR2, Currie CJ1
1Cardiff University, Cardiff, UK; 2University Hospital of Wales, Cardiff,
UK
OBJECTIVE: Type-2 diabetes (T2DM) is associated with
increased morbidity and mortality; however, the onset can be
delayed. This study quantiﬁed the impact of delaying the onset
of frank diabetes on the rate of progression to vascular compli-
cations and all associated costs. METHODS: The Cardiff Dia-
betes Simulation Model was run over a 20-year time horizon
following a cohort of 1000 newly diagnosed T2DM patients
compared to a cohort whose T2DM was delayed by two or ten
years. The model utilised the Framingham equations to predict
cardiovascular events before diabetes and the UKPDS equations
following diagnosis. The transition of predicted risk from 
Framingham to the UKPDS risk level was modelled assuming 
an instantaneous switch (Scenario 1) or a linear-progression
between risk equations (Scenario 2). Direct health care costs
[2004, GBP] and outcomes were each discounted at 3.5%.
RESULTS: Assuming no delay in diabetes, the model predicted
501 myocardial infarctions (MI’s), 252 strokes and 2505
microvascular events. Mean costs and quality adjusted life years
(QALY’s) per subject were £11,972 and 7.3 years, respectively.
Mean costs savings ranged from -£2376 to -£4791 (Scenario 1)
and -£123 to -£573 (Scenario 2) through delaying diabetes by
two and ten years, respectively. Mean change in QALY’s ranged
from 0.6 to 1.7 years (Scenario 1) and 0.1 to 1.2 (Scenario 2),
respectively. The number of MI’s avoided ranged from 40 to 224;
while the predicted number of strokes avoided ranged from 37
to 147 for a two-year and ten-year delay, respectively. CON-
CLUSIONS: This study demonstrated that even modest delays
in the onset of diabetes can have a substantial impact on pre-
dicted vascular events and ﬁnancial costs. However, the magni-
tude of this impact was highly dependent upon the modelling
assumption employed relating to the change in cardiovascular
risk as people progress to frank T2DM.
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EFFECT OF GLYCEMIC CONTROL ON HEALTH CARE COSTS
Secnik K1, Oglesby A1, Shetty S2, Lage MJ3
1Eli Lilly and Company, Indianapolis, IN, USA; 2i3 Magniﬁ, Eden Prairie,
MN, USA; 3HealthMetrics Outcomes Research, Groton, CT, USA
OBJECTIVE: Glycosylated hemoglobin (HbA1c) is a well-
established measure of glycemic control. Understanding the
impact of staying at target HbA1c levels (£7.0%) on treatment
costs would be of great signiﬁcance to managed care organiza-
tions. The goal of this study was to determine whether being at
target HbA1c results in reductions in diabetes-related costs.
METHODS: This study was a retrospective database analysis
using eligibility, medical and pharmacy claims data, and labora-
tory data from a large US health care organization. Subjects were
included in the study if they had two or more claims for type-2
diabetes and at least one HbA1c value during the period January
1, 2002 through December 31, 2002 (ﬁrst such date identiﬁed
as index date). Subjects with two or more claims for type-1 dia-
betes were excluded from the study. Study subjects were divided
into those at target HbA1c (£7.0%) and above target HbA1c
(>7.0%) and were followed for a period of one year following
their index date. Demographic, clinical and cost variables were
extracted for each subject. Multiple linear regression analysis
was used to compare treatment costs between subjects at target
level and subjects above target level. RESULTS: A total of 3121
subjects were identiﬁed as being continuously at target level and
3659 subjects were identiﬁed as being continuously above target
level. The target group was associated with 30% lower total 
diabetes costs (p < 0.01) after controlling for the confounding
factors (age, gender, health plan region and presence of co-
morbid conditions). The predicted total diabetes costs in the
target group was $1171 and the predicted costs in the above
target group was $1540. CONCLUSION: Results of this analy-
sis suggests that staying at target HbA1c level was associated with
cost savings over a one-year follow-up period in a managed care
setting.
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COST OF DIABETES COMPLICATIONS IN FRANCE,
GERMANY, ITALY AND SPAIN
Palmer AJ1, Ray JA1, Roze S1,Valentine WJ1, Secnik K2, Oglesby A2
1CORE—Center for Outcomes Research, Binningen, Basel,
Switzerland; 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To collect cost data on the complications of 
diabetes from published sources in France, Germany, Spain and
Italy for use in a peer-reviewed, validated diabetes model.
METHODS: A search for published cost of diabetes complica-
tions data was performed in peer-reviewed journals listed in
PubMed and ISPOR conference proceedings from the last ten
years. Where country-speciﬁc data were not available, we
referred to government websites and local cost experts. Identi-
ﬁed costs were inﬂated to 2004 Euros (€). Major complication
